Patented Drugs Tariffs in the US 2026
On Thursday, April 3, 2026 — the first anniversary of President Donald Trump’s original “Liberation Day” tariff sweep — the United States government signed one of the most consequential pharmaceutical trade actions in modern American history. Invoking Section 232 of the Trade Expansion Act of 1962, the same national security authority previously used to impose tariffs on steel and aluminium, President Trump signed an executive order imposing a 100% ad valorem tariff on all imported patented pharmaceuticals and their associated active pharmaceutical ingredients (APIs) from countries that have not reached reshoring or Most Favoured Nation (MFN) pricing agreements with the US administration. The policy targets branded, patented drugs — the high-value, innovative medicines used to treat cancer, rare diseases, autoimmune disorders, and infectious diseases — and applies to imports from major manufacturing hubs including China, India, Singapore, and others that have not signed bilateral deals with Washington. The tariffs are designed to achieve two simultaneous goals: force pharmaceutical companies to lower US drug prices through MFN pricing agreements, and compel them to reshore manufacturing back to the United States by making foreign production economically punishing.
The executive order is not a blunt instrument. It comes loaded with a tiered, negotiated architecture of exemptions, phase-in timelines, country-specific rates, and compliance pathways that reflect months of behind-the-scenes bargaining between the White House and the pharmaceutical industry. Generic drugs, biosimilars, orphan drugs, gene therapies, nuclear medicines, fertility treatments, plasma-derived therapies, and antibody drug conjugates are all exempt — at least for now. Countries including the European Union, Japan, South Korea, and Switzerland face a reduced 15% tariff rate, while the United Kingdom faces a 10% rate that could drop to zero under a future bilateral pharmaceutical agreement. Companies that have signed MFN pricing deals and commit to building US manufacturing facilities face a 0% tariff until January 20, 2029. And critically, 13 major pharmaceutical companies have already signed MFN deals with the Trump administration — including Pfizer, Eli Lilly, Bristol Myers Squibb, and Novo Nordisk — meaning many of the world’s largest drugmakers are already partially or fully shielded from the steepest rates. The White House claims the threat of these tariffs has already generated approximately $400 billion in new investment commitments to reshore pharmaceutical manufacturing to the United States during Trump’s current term.
Interesting Facts About Tariffs on Patented Drugs in the US 2026
Here are the most striking and verified facts about Trump’s patented drug tariff policy, signed into effect on April 3, 2026 — all drawn directly from White House official proclamations, the executive order text, CNBC, Newsweek, Al Jazeera, The Hill, and other verified sources as of today.
| # | Fact | Detail |
|---|---|---|
| 1 | Tariff rate on patented drugs | 100% ad valorem duty on imported patented pharmaceuticals and APIs — the headline rate |
| 2 | Legal authority used | Section 232 of the Trade Expansion Act of 1962 — national security authority |
| 3 | Date signed | April 3, 2026 — the first anniversary of Trump’s original “Liberation Day” tariff sweep |
| 4 | Effective date — large companies | July 31, 2026 (120 days from signing) |
| 5 | Effective date — smaller companies | September 29, 2026 (180 days from signing) |
| 6 | Tariff for MFN deal + onshoring companies | 0% — through January 20, 2029 |
| 7 | Tariff for onshoring-only companies (no MFN deal) | 20% — rising to 100% within 4 years |
| 8 | EU, Japan, South Korea, Switzerland tariff | 15% — aligned with existing trade frameworks |
| 9 | United Kingdom tariff | 10% — may reduce to 0% under future US-UK pharmaceutical agreement |
| 10 | Generic drugs tariff | 0% — exempt at this time — to be reassessed within 1 year |
| 11 | MFN pricing deals already signed | 13 companies have signed; 4 more in active negotiations (CNBC, April 2, 2026) |
| 12 | Major companies with MFN deals | Pfizer, Eli Lilly, Bristol Myers Squibb, Novo Nordisk, Boehringer, GSK among 13+ |
| 13 | $400 billion investment commitment | White House claims Section 232 threat already triggered ~$400 billion in US pharma manufacturing investment pledges |
| 14 | PhRMA estimate: tariff cost to US | Report projects tariffs would raise US drug costs by nearly $51 billion per year and US prices by up to 12.9% |
| 15 | Categories fully exempt from tariffs | Generic drugs, biosimilars, orphan drugs, nuclear medicines, gene therapies, fertility treatments, plasma-derived therapies, antibody drug conjugates, animal health drugs |
| 16 | Countries primarily affected at 100% | China, India, Singapore, and others without separate trade or MFN agreements |
| 17 | India’s near-term exposure | Generics (India’s primary US export) exempt — but patented drug and API supply chains at risk |
| 18 | Supreme Court precedent | The earlier IEEPA “Liberation Day” tariffs were struck down by the Supreme Court in February 2026; this policy uses Section 232 — a different, court-tested legal authority |
| 19 | PhRMA CEO statement | Stephen J. Ubl: tariffs “on cutting-edge medicines will increase costs and could jeopardize billions in US investments” |
| 20 | US USTR statement | Jamieson Greer: the focus is “less what’s the tariff level, and it’s more all of the actual deals… to make sure that the supply chains are secure that we’re making here in America” |
Source: White House Presidential Proclamation — Adjusting Imports of Pharmaceuticals (April 3, 2026); White House Fact Sheet (April 3, 2026); CNBC (April 2, 2026); The Hill (April 3, 2026); Newsweek (April 3, 2026); Al Jazeera (April 3, 2026); Business Standard (April 3, 2026); Axios (April 2, 2026); Pharmaceutical Commerce (December 2025); PhRMA; Washington Examiner (April 3, 2026)
The architecture of this tariff policy is more sophisticated than the headline rate suggests, and understanding the architecture is essential to understanding its real-world impact. The 100% rate is a ceiling and a threat, not a flat universal tax — and that is deliberate. By creating multiple off-ramps (MFN pricing deals, onshoring agreements, country-specific rates), the administration is using the tariff mechanism as a negotiating tool rather than purely a revenue instrument. The $400 billion in already-committed US pharmaceutical manufacturing investment that the White House cites as a pre-tariff effect is the most telling evidence that the strategy is working as intended: companies have been reshoring in anticipation of exactly this moment for over a year, ever since the Commerce Department launched its Section 232 investigation in April 2025. The tariff announcement on April 3 is in many ways the formalisation of a negotiated outcome that has been taking shape in the background for many months.
What makes this policy structurally different from ordinary trade tariffs is that it ties import costs to pharmaceutical pricing policy in the domestic market. The MFN pricing mechanism — which requires companies to ensure that US patients pay no more than the lowest price charged in comparable wealthy markets globally — is a tool for addressing the long-standing problem of Americans paying dramatically more for branded drugs than citizens of peer nations. By linking tariff exemption to MFN compliance, the administration is effectively embedding a drug pricing reform programme inside a trade policy framework, using the threat of 100% import duties as leverage to achieve what direct price regulation has struggled to deliver through legislation.
Tariff Rate Structure for Patented Drugs 2026
| Company / Country Scenario | Tariff Rate | Conditions |
|---|---|---|
| MFN pricing deal + active US onshoring commitment | 0% | Both conditions required; tariff-free through January 20, 2029; US plant must be completed by Jan 2029 |
| US onshoring commitment only (no MFN deal) | 20% — rising to 100% within 4 years | Company must have Commerce Dept-approved onshoring plan |
| EU, Japan, South Korea, Switzerland / Liechtenstein | 15% | Aligned with broader bilateral trade frameworks |
| United Kingdom | 10% | Could drop to 0% under future US-UK pharmaceutical pricing agreement; UK government has raised drug prices to lower US burden |
| All other countries (India, China, Singapore, etc.) | 100% | No MFN deal, no onshoring agreement, no existing trade framework |
| Generic drugs — all countries | 0% (exempt at this time) | To be reassessed within 1 year; Commerce Dept to evaluate generics reshoring status |
| Biosimilars — all countries | 0% (exempt at this time) | Same conditions as generics |
| Orphan drugs (all approved indications orphan-designated) | 0% exempt | Per the Orphan Drug Act (21 U.S.C. 360aa et seq.) |
| Nuclear medicines | 0% exempt | |
| Gene therapies / cell therapies | 0% exempt | |
| Fertility treatments | 0% exempt | |
| Plasma-derived therapies | 0% exempt | |
| Antibody drug conjugates | 0% exempt | |
| Medical countermeasures (CBRN threats) | 0% exempt | Chemical, biological, radiological, nuclear threat countermeasures |
| Animal health pharmaceuticals | 0% exempt | |
| Strategic API Reserve purchases | 0% exempt | Included in the generic pharmaceuticals exemption |
Source: White House Presidential Proclamation — Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States (April 3, 2026); White House Fact Sheet (April 3, 2026); The Hill (April 3, 2026); CNBC (April 2, 2026); PharmExec (April 3, 2026); Business Standard (April 3, 2026)
The exemption list is as important as the tariff rates themselves, because it reveals the careful political and policy architecture behind what might otherwise look like a blunt protectionist measure. Orphan drugs, gene therapies, cell therapies, fertility treatments, plasma-derived therapies, antibody drug conjugates, and nuclear medicines together represent a substantial portion of the most advanced and clinically critical drugs available to US patients — and by exempting all of them, the administration has insulated itself from the most damaging criticism that the tariffs could harm vulnerable patients who depend on cutting-edge treatments. The decision to exempt generics and biosimilars is equally strategic: given that Indian pharmaceutical companies supply approximately 40% of all generic prescriptions dispensed in the United States, imposing tariffs on generics would have immediately and visibly raised prices at the pharmacy counter for everyday Americans, creating exactly the political backlash the administration is trying to avoid.
The UK-specific 10% rate deserves particular attention as a window into how this tariff regime functions as diplomatic leverage. The UK received a preferential rate in direct exchange for the British government raising its own pharmaceutical pricing — the National Health Service effectively agreeing to pay more for branded drugs, which in turn allows those same manufacturers to lower their US prices to meet MFN requirements. This is a live demonstration of how the MFN mechanism is designed to work globally: by making the rest of the world pay more while the US pays less (or, as critics argue, by reducing the cross-subsidisation that has historically made cheap drug access in other countries possible while the US has funded global R&D through higher prices).
MFN Pricing Deals and Industry Response Statistics 2026
| MFN / Industry Parameter | Data |
|---|---|
| MFN pricing deals signed (as of April 3, 2026) | 13 companies have fully signed |
| MFN deals in active negotiation | 4 more companies in active negotiations (CNBC, April 2, 2026) |
| Named companies with MFN deals | Pfizer, Eli Lilly, Novo Nordisk, Bristol Myers Squibb, Boehringer, GSK — among 13+ |
| First company to sign MFN deal | Pfizer — cited as first pharma to strike a drug pricing deal with the White House (BioSpace, Jan 2026) |
| PhRMA: projected cost increase | Tariffs would raise US drug costs by ~$51 billion per year |
| PhRMA: projected price increase | US drug prices could rise by up to 12.9% under the tariff regime |
| PhRMA CEO quote (Stephen J. Ubl) | Tariffs “on cutting-edge medicines will increase costs and could jeopardize billions in US investments” |
| Total pharma manufacturing investment pledged (US) | ~$400 billion committed by US and foreign pharma companies for US-based plants during Trump’s term (White House Fact Sheet) |
| US drug price increases in 2026 | Pharma companies plan to raise prices on at least 350 branded medications in 2026 vs ~250 in 2025 (Reuters / 3 Axis Advisors data) |
| Median drug price increase 2026 | 4% — same as 2025; in line with average since 2019 |
| Pfizer 2026 price increases | Raising prices on 80 products — more than any other company — including Ibrance, Nurtec, Paxlovid |
| Industry companies reshoring | Regeneron, Roche, Merck, ThermoFisher actively reshoring US production |
| Piramal Pharma US investment | $90 million into plants in Lexington, KY and Riverview, MI |
| Section 232 pharma probe launched | April 2025 — Commerce Department investigation began |
| Broad Liberation Day tariffs fate | Struck down by US Supreme Court in February 2026 (imposed under IEEPA) |
Source: CNBC (April 2, 2026); White House Fact Sheet (April 3, 2026); PharmExec (April 3, 2026); Al Jazeera (April 3, 2026); Newsweek (April 3, 2026); The Hill (April 3, 2026); BioSpace (January 2026); Pharmaceutical Commerce (December 2025); Washington Examiner (April 3, 2026); Axios (April 2, 2026)
The 13 MFN deals already signed represent the administration’s most powerful argument that the tariff threat is working. Before any tariffs actually took effect, major pharmaceutical companies had already volunteered pricing commitments in exchange for tariff exemption — committing to launch new drugs at lower US prices and, in some cases, to price existing drugs closer to international benchmarks. The $400 billion in investment pledges represents a number that, if delivered, would mark the most significant reshoring of pharmaceutical manufacturing capacity in American history. Currently, the US is heavily dependent on overseas production for both finished drug products and the active pharmaceutical ingredients that go into them — a vulnerability that was dramatically exposed during the COVID-19 pandemic when supply chain fragility became a national security issue for the first time in a generation.
The tension in the data, however, is real. Even as the MFN deals are being struck and investment pledges accumulate, the pharmaceutical industry is simultaneously raising prices on 350+ branded drugs in 2026 — including Pfizer, which signed the first MFN deal. PhRMA’s own commissioned report estimates that the tariff regime could raise US drug costs by $51 billion per year and prices by up to 12.9% — a figure that would represent a significant burden for patients, insurers, and government health programmes. The administration disputes this framing, arguing that the MFN mechanism will net-lower drug prices over time and that the investment in domestic manufacturing is a strategic imperative that justifies short-term disruption. This fundamental argument — tariffs as reform tool versus tariffs as cost inflation mechanism — is one that the markets, patients, and policymakers will be navigating for years.
Impact of Patented Drug Tariffs on India Statistics 2026
| India Pharma Parameter | Data |
|---|---|
| India’s primary US export category | Generic medicines — currently fully exempt from tariffs |
| India’s share of US generic drug prescriptions | Indian companies supply approximately 40% of all generic prescriptions dispensed in the US |
| India’s vulnerability — patented drugs | Companies importing patented drugs to the US without an approved reshoring plan face 100% tariffs |
| India’s vulnerability — APIs | API supply chains to multinational branded drug manufacturers potentially disrupted |
| Biocon CEO assessment | “The current framework is targeted at branded and patented drugs, with generics and biosimilars largely exempt, which limits any immediate disruption for Indian players like Biocon” — Siddharth Mittal, Biocon CEO |
| Generics exemption re-evaluation | Commerce Department to evaluate generics reshoring status within 1 year and potentially impose tariffs on generics at that time |
| India’s contract manufacturing role | Critical supplier of intermediates and contract manufacturing services to multinational pharmaceutical companies |
| Long-term investment risk | Incentives for R&D and onshoring to US may redirect future investment away from India |
| Logistics and supply chain costs | Rising costs due to Middle East conflict disrupting shipping routes and increasing insurance costs — compounding tariff pressure |
| India’s strategic response opportunity | Industry voices calling for India to use tariff pressure as a “wake-up call” to shift from generic dominance to innovation and drug discovery |
| India tariff rate — patented drugs | 100% — unless individual companies sign reshoring/MFN agreements with the US Commerce Department |
| Key risk area — contract manufacturers | Indian firms acting as intermediates or ingredients suppliers to Western branded drug companies may see orders redirected to US-based suppliers |
Source: ANI / The Tribune India (April 3, 2026); Business Standard (April 3, 2026); ANI / Republic World (April 3, 2026); Biocon CEO Siddharth Mittal statement (New Kerala, April 3, 2026); EveryLife Foundation; CNBC (April 2, 2026); New Kerala (April 3, 2026)
India’s situation with the new tariff regime is genuinely mixed — and importantly different from what the headline 100% rate might initially suggest. Because generic pharmaceuticals are the overwhelming majority of what India exports to the United States, and because those generics are explicitly exempt from the Section 232 tariffs at this time, the immediate disruption to the Indian pharmaceutical industry is limited. This was immediately acknowledged by industry leaders: Biocon’s CEO was clear that the near-term impact on companies like Biocon — which operates primarily in the biosimilars and generics space — would be minimal under the current policy framework. Indian drugmakers that dominate the US generics market are unlikely to face immediate cost pressure, and their US customers — primarily insurance companies, pharmacy benefit managers, and hospital systems — will not see price increases attributable to these tariffs on their generic formulary purchases.
The more complex picture emerges when you look at the supply chain connections between Indian companies and the patented drug market. India plays a critical role not just as a finished-goods manufacturer of generics but as a producer of active pharmaceutical ingredients, intermediates, and contract manufacturing services that feed into the patented drug supply chains of multinational pharmaceutical companies. A European or American branded drug manufacturer facing 100% tariffs on its finished patented drug may over time seek to restructure its supply chain to qualify for tariff exemptions — which could mean shifting API sourcing or contract manufacturing from Indian facilities to US-based ones. That structural shift, if it materialises at scale, would be more damaging to the Indian pharmaceutical sector than the direct tariff exposure on finished generic products. The one-year review clock on the generics exemption is also a significant source of medium-term uncertainty: if the Commerce Department determines that generics reshoring has been insufficient, the tariff-free status of India’s most important US exports could be revisited as early as April 2027.
Global Country Tariff Rates for Pharmaceutical Imports 2026
| Country / Region | Tariff Rate — Patented Drugs | Status / Condition |
|---|---|---|
| United States domestic production | 0% | N/A — not an import |
| MFN deal + onshoring (any country) | 0% through January 20, 2029 | Requires both MFN pricing agreement (HHS) AND Commerce Dept-approved onshoring plan |
| European Union | 15% | Aligned with existing US-EU trade frameworks |
| Japan | 15% | Aligned with existing US-Japan trade framework |
| South Korea | 15% | Aligned with existing US-South Korea trade framework |
| Switzerland / Liechtenstein | 15% | Aligned with existing US-Switzerland trade framework |
| United Kingdom | 10% | UK government raised NHS drug prices; rate can reduce to 0% under future US-UK pharma pricing deal |
| India | 100% | No MFN deal; no existing trade framework at country level |
| China | 100% | No MFN deal; no existing trade framework at country level |
| Singapore | 100% | Major manufacturing hub; no existing trade framework |
| Other countries (without trade deals or MFN) | 100% | Default rate absent bilateral agreement |
| Companies with onshoring plan only (no MFN) | 20% rising to 100% in 4 years | Available to companies from any country with Commerce Dept-approved reshoring plan |
| Generic drugs — all countries | 0% (exempt) | Subject to 1-year review |
| Biosimilars — all countries | 0% (exempt) | Subject to 1-year review |
Source: White House Presidential Proclamation (April 3, 2026); White House Fact Sheet (April 3, 2026); Business Standard (April 3, 2026); ANI (April 3, 2026); The Hill (April 3, 2026); Axios (April 2, 2026); CNBC (April 2, 2026); Newsweek (April 3, 2026)
The five-tier country framework — zero for MFN+onshoring, 10% for UK, 15% for EU/Japan/South Korea/Switzerland, 20% for onshoring-only, and 100% for everyone else — maps almost precisely onto the geopolitical hierarchy of US trade relationships in 2026. The countries at 15% are the US’s closest pharmaceutical manufacturing allies in the EU and Asia-Pacific, all of which have existing trade frameworks that the administration chose to honour rather than override. The UK’s 10% rate reflects the most recent and operationally specific deal — the British government’s agreement to raise NHS drug prices in exchange for a preferential tariff position demonstrates that MFN pricing is a bilateral as well as a corporate-level mechanism. The arrangement with the UK also shows that the zero-percent pathway exists at the national level, not just the company level, for governments willing to restructure their own pharmaceutical pricing markets to align with US preferences.
The 100% rate for India, China, Singapore, and other major pharmaceutical manufacturing hubs is the sharpest edge of this policy, and it reflects both the strategic objective (breaking dependence on these supply chains) and the geopolitical calculus (India and China are the two largest non-allied producers of generic and speciality pharmaceutical products in the world, and neither has existing comprehensive trade agreements with the US that would qualify their exports for preferential treatment). The question of whether these countries will successfully negotiate bilateral pharmaceutical agreements — as the UK has done — or whether individual companies operating in those countries will sign MFN and onshoring deals to escape the 100% rate is one that will play out over the 120-day and 180-day phase-in windows that begin today.
Section 232 Pharmaceutical Tariff Policy — Key Background Statistics 2026
| Policy Background Parameter | Data |
|---|---|
| Executive authority invoked | Section 232 of the Trade Expansion Act of 1962 |
| Previous Section 232 uses | Steel (25%), aluminium (10/25%), automobiles — now applied to pharmaceuticals for the first time |
| Section 232 probe launched | April 2025 — Commerce Department investigation into pharma imports and national security |
| Executive order signed | April 3, 2026 (April 2, 2026 US date) |
| Trump’s stated justification | Pharmaceuticals “are being imported into the United States in such quantities… as to threaten to impair the national security of the United States” |
| Key national security finding | US is “heavily reliant on imports, threatening to limit U.S. access to life-saving medications in the event of global supply chain disruption” |
| Related August 2025 EO | Trump signed Executive Order (August 2025) to fill the Strategic API Reserve for pharmaceutical supply chain resilience |
| Adjacent Section 232 probes launched | Personal protective equipment (PPE), medical consumables, medical devices, robotics |
| Previous broad tariff fate | “Liberation Day” tariffs (IEEPA authority) struck down by US Supreme Court, February 2026 — Section 232 is a different, more established legal authority |
| USTR Jamieson Greer statement | Policy focus is “less what’s the tariff level, and it’s more all of the actual deals we’ve been making with countries and companies to make sure that the supply chains are secure” |
| Trump tariff anniversary | Signed on first anniversary of original “Liberation Day” — April 2025 — which “triggered major reactions in global markets and significantly altered international trade dynamics” |
| Steel/aluminium tariff revision (same day) | Products with <15% metal content — standard country duty only; products with >15% metal content — flat 25% tariff on full product value |
| HHS enforcement role | Department of Health and Human Services manages MFN pricing agreements |
| Commerce Department enforcement role | Manages onshoring agreements; evaluates generics reshoring within 1 year; conducts external audits |
Source: White House Presidential Proclamation (April 3, 2026); White House Fact Sheet (April 3, 2026); Newsweek (April 3, 2026); Business Standard (April 3, 2026); Washington Examiner (April 3, 2026); The Hill (April 3, 2026); Axios (April 2, 2026); New Kerala (April 3, 2026); FiercePharma (April 3, 2026)
The choice of Section 232 as the legal mechanism for pharmaceutical tariffs is both strategically and legally significant. The Trump administration’s previous effort to impose sweeping global tariffs — the so-called “Liberation Day” tariffs announced in April 2025, imposed under the International Emergency Economic Powers Act (IEEPA) — was struck down by the US Supreme Court in February 2026. That legal defeat forced a fundamental pivot in trade strategy: the administration needed to find an authority that courts would not overturn, and Section 232’s national security framing — which has survived legal challenge in the steel and aluminium context — fit the bill. By finding that pharmaceutical imports “threaten to impair the national security” of the United States, the Commerce Department’s Section 232 report provides the legal predicate for tariffs that are far more defensible in court than the broad IEEPA authority that was overturned.
The Strategic API Reserve, which Trump directed be filled through an August 2025 executive order, and the Section 232 probes into PPE, medical consumables, medical devices, and robotics paint a picture of a broader administration strategy to use national security frameworks to rebuild domestic manufacturing capacity across the full range of products that COVID-19 revealed to be critically dependent on foreign supply chains. The pharmaceutical tariffs announced today are the flagship action in that strategy — the highest-profile and most commercially significant sector covered. They are unlikely to be the last: the administration has signalled that medical equipment and devices will face similar scrutiny, and the one-year review of the generics exemption creates a calendar event in April 2027 at which the tariff net could dramatically expand.
Pharmaceutical Industry and Drug Price Impact Statistics 2026
| Impact Parameter | Data / Projection |
|---|---|
| Projected annual cost increase (PhRMA estimate) | ~$51 billion per year added to US drug costs under full tariff scenario |
| Projected US price increase (PhRMA estimate) | Up to 12.9% increase in US drug prices |
| Number of branded drugs with price increases in 2026 | At least 350 branded medications with price increases vs ~250 in 2025 |
| Median branded drug price increase (2026) | 4% — same as 2025; consistent with post-2019 trend |
| Pfizer drugs with price increases (2026) | 80 products — most of any company including Ibrance, Nurtec, Paxlovid |
| US branded pharma market (global context) | US pays significantly more for branded drugs than EU, Japan, UK — MFN seeks to close the gap |
| Industries affected beyond pharma | Steel, aluminium, copper tariff revision impacts Indian metal exporters and global supply chains |
| Steel/aluminium change | Products with >15% metal by weight: 25% flat tariff on full value regardless of metal composition |
| Products with <15% metal by weight | Standard country duty only — no separate metals tariff |
| Drug companies reshoring: examples | Regeneron, Roche, Merck, ThermoFisher, Piramal Pharma ($90M US investment) |
| Production timeline challenge | Building a pharmaceutical manufacturing facility typically takes 3–5+ years |
| MFN mechanism: goal | Ensure US patients pay no more than the lowest price charged in comparable wealthy markets globally |
| Innovation risk (American Action Forum, 2020 projection) | MFN pricing policy in Medicare Part B alone projected to result in 60 fewer drugs launching over a decade |
| Drugmakers with onshoring plans underway | Eli Lilly, Pfizer among companies that have announced US manufacturing plant developments |
Source: Pharmaceutical Commerce (December 2025); BioSpace (January 2026); PharmExec (April 3, 2026); White House Fact Sheet (April 3, 2026); CNBC (April 2, 2026); Newsweek (April 3, 2026); Washington Examiner (April 3, 2026); Business Standard (April 3, 2026); FiercePharma (April 3, 2026)
The PhRMA estimate of $51 billion in additional annual US drug costs and a 12.9% price increase is the number the industry’s opponents of the tariff policy will cite most persistently — and it deserves scrutiny in both directions. PhRMA commissioned this analysis, which means it should be read with the same scepticism applied to any industry-funded impact assessment. The pharmaceutical industry has strong financial incentives to argue that tariffs will raise prices, because that narrative supports their position that tariffs are harmful to patients and should be withdrawn. At the same time, it would be naïve to dismiss the cost estimate entirely: supply chains do not reorganise without disruption, manufacturing facilities do not materialise in months, and if companies that do not qualify for exemptions face 100% additional import costs, some portion of those costs will flow through to payers and patients.
The 350+ drugs with price increases in 2026 — many from companies that have already signed MFN deals — is a counterintuitive data point that cuts against the administration’s narrative. If MFN deals are designed to lower prices, why are signatory companies raising prices on so many products simultaneously? The answer lies in the structure of the MFN agreements: they apply primarily to the launch prices of new drugs, not necessarily to the existing portfolio of already-approved products. Companies can comply with MFN commitments on future launches while continuing to raise prices on established products that are not covered by those agreements. This distinction between the forward-looking pricing reform the administration is pursuing and the current pricing reality is the core tension that the tariff policy has not yet resolved — and may not resolve before Trump’s term ends in January 2029.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
